Lexaria Bioscience Corp. (NASDAQ: LEXX) has achieved FDA clearance for its Investigational New Drug (IND) application, allowing the company to proceed with its planned U.S. Phase 1b clinical trial, HYPER-H23-1, for hypertension. This trial will evaluate the effectiveness of Lexaria's patented DehydraTECH-CBD in individuals with stage 1 or stage 2 hypertension.
The HYPER-H23-1 trial, formally titled "A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension," will explore the therapeutic potential of DehydraTECH-CBD. The study aims to build upon the success of Lexaria's previous human clinical trials, which have demonstrated positive results regarding the technology's impact.
DehydraTECH Technology
Lexaria's DehydraTECH is a drug delivery platform designed to enhance the bioavailability of active pharmaceutical ingredients (APIs). By improving how APIs enter the bloodstream, DehydraTECH aims to increase the effectiveness of treatments. John Docherty, President of Lexaria, emphasized the significance of this milestone as a demonstration of DehydraTECH's viability, particularly in the context of hypertension management.
Trial Objectives and Design
The Phase 1b trial is designed to primarily assess the safety and tolerability of DehydraTECH-CBD in hypertensive patients. Secondary objectives include evaluating the efficacy of DehydraTECH-CBD in reducing blood pressure and conducting detailed pharmacokinetic testing. The trial will be a randomized, double-blind, placebo-controlled study.
Previous Studies and Future Directions
Lexaria is looking to build on five previously successful human clinical trials, which studied DehydraTECH-processed CBD in a total of 134 individuals. The company also plans to expand its research into GLP-1 studies in 2024, further exploring the therapeutic potential of its DehydraTECH technology.
